Infection Clinical Trial
Official title:
Impact of Genotyping P450 2C19 on Hospitalization Period When Voriconazole Treatment is Started
Monocentric study with the objective to evaluate the impact of genotyping CYP2C19 on the hospitalization period. The genotyping will permit to adapt at best the Voriconazole posology.
The main objective of this multi-center study is to evaluate the impact of dose adjustment of
Voriconazole after CYP2C19 genotyping at the start of treatment, on the length of hospital
stay.
Thus, a new strategy will be proposed as part of this project and will be compared to the
reference strategy:
The New strategy: genotyping of CYP2C19 in any patient receiving treatment with Voriconazole
in order to better adapt the treatment regimen as quickly as possible (increase of the dosage
of Voriconazole in high-speed metabolisers or use of another antifungal, decreased dosage in
poor metabolisers).
The Reference strategy: pharmacological therapeutic monitoring of Voriconazole allowing an
adaptation of the Voriconazole dosage based on the residual concentration measured once
steady state has been reached (5 elimination half-lives).
Multicenter, randomized study comparing two strategies of Voriconazole adaptation according
to whether or not genotyping of CYP2C19 is performed as soon as Voriconazole is started.
Thus, the new strategy tested in this project and compared to the reference strategy
(adaptation of Voriconazole dosage depending on the residual concentration), will be a
genotyping of CYP2C19 in any patient receiving a treatment based on Voriconazole in order to
better adapt the treatment regimen as quickly as possible (increase in the dosage of
Voriconazole or use of another antifungal agent in ultra-rapid metabolisers, decrease in
dosage in poor metabolisers).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04529421 -
Assocation Between In-person Instruction and COVID-19 Risk
|
||
| Recruiting |
NCT04081792 -
Optimal Antibiotics for Operated Diabetic Foot Infections
|
N/A | |
| Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
| Recruiting |
NCT04674657 -
Does Extra-Corporeal Membrane Oxygenation Alter Antiinfectives Therapy Pharmacokinetics in Critically Ill Patients
|
||
| Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
| Recruiting |
NCT00342589 -
New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia
|
||
| Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
| Completed |
NCT03296423 -
Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly
|
Phase 4 | |
| Withdrawn |
NCT04217252 -
Clinical Application of High-throughput Sequencing Technology for the Diagnosis of Patients With Severe Infection
|
N/A | |
| Recruiting |
NCT02905552 -
Myelodysplasic Syndromes and Risk Factors for Infection
|
N/A | |
| Recruiting |
NCT02899143 -
Short-course Antimicrobial Therapy in Sepsis
|
Phase 2 | |
| Withdrawn |
NCT02904434 -
Gastrointestinal Implications of Voriconazole Exposure
|
||
| Active, not recruiting |
NCT02768454 -
Antimicrobials Stewardship by Pharmacist
|
N/A | |
| Completed |
NCT02219776 -
Decreasing Infection In Arthroscopic Shoulder Surgery
|
N/A | |
| Completed |
NCT02210169 -
RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates
|
N/A | |
| Recruiting |
NCT02098226 -
Evaluation of MALDI Biotyper CA System for Detection of Gram- and Gram+ Bacteria and Yeasts
|
N/A | |
| Completed |
NCT01846832 -
A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection
|
Phase 3 | |
| Completed |
NCT01434797 -
Value of PET/CT Imaging in the Diagnosis of Permanent Central Venous Catheters Infection
|
||
| Terminated |
NCT01441206 -
Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants
|
Phase 1 | |
| Completed |
NCT01159834 -
Human Papillomavirus (HPV) Vaccination in Barretos (Pio XII Foundation - Barretos Cancer Hospital)
|
N/A |